Beacon Pharmaceuticals Statistics

Total Valuation

Beacon Pharmaceuticals has a market cap or net worth of BDT 27.00 billion. The enterprise value is 36.83 billion.

Market Cap	27.00B
Enterprise Value	36.83B

Important Dates

The last earnings date was Sunday, September 29, 2024.

Earnings Date	Sep 29, 2024
Ex-Dividend Date	Oct 28, 2024

Share Statistics

Beacon Pharmaceuticals has 231.00 million shares outstanding. The number of shares has increased by 0.00% in one year.

Shares Outstanding	231.00M
Shares Change (YoY)	+0.00%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	30.01%
Owned by Institutions (%)	0.33%
Float	161.69M

Valuation Ratios

The trailing PE ratio is 57.95.

PE Ratio	57.95
Forward PE	n/a
PS Ratio	2.73
PB Ratio	4.41
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.15, with an EV/FCF ratio of -10.35.

EV / Earnings	79.03
EV / Sales	3.72
EV / EBITDA	19.15
EV / EBIT	27.39
EV / FCF	-10.35

Financial Position

The company has a current ratio of 1.35, with a Debt / Equity ratio of 1.65.

Current Ratio	1.35
Quick Ratio	0.38
Debt / Equity	1.65
Debt / EBITDA	5.26
Debt / FCF	-2.84
Interest Coverage	1.33

Financial Efficiency

Return on equity (ROE) is 7.59% and return on invested capital (ROIC) is 5.82%.

Return on Equity (ROE)	7.59%
Return on Assets (ROA)	5.24%
Return on Capital (ROIC)	5.82%
Revenue Per Employee	2.55M
Profits Per Employee	120,347
Employee Count	3,872
Asset Turnover	0.62
Inventory Turnover	2.36

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -49.35% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-49.35%
50-Day Moving Average	126.44
200-Day Moving Average	184.72
Relative Strength Index (RSI)	41.69
Average Volume (20 Days)	210,334

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Beacon Pharmaceuticals had revenue of BDT 9.89 billion and earned 465.98 million in profits. Earnings per share was 2.02.

Revenue	9.89B
Gross Profit	4.99B
Operating Income	1.34B
Pretax Income	542.62M
Net Income	465.98M
EBITDA	1.92B
EBIT	1.34B
Earnings Per Share (EPS)	2.02

Full Income Statement

Balance Sheet

The company has 300.46 million in cash and 10.12 billion in debt, giving a net cash position of -9.82 billion or -42.52 per share.

Cash & Cash Equivalents	300.46M
Total Debt	10.12B
Net Cash	-9.82B
Net Cash Per Share	-42.52
Equity (Book Value)	6.12B
Book Value Per Share	26.50
Working Capital	3.10B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.62 billion and capital expenditures -1.94 billion, giving a free cash flow of -3.56 billion.

Operating Cash Flow	-1.62B
Capital Expenditures	-1.94B
Free Cash Flow	-3.56B
FCF Per Share	-15.41

Full Cash Flow Statement

Margins

Gross margin is 50.42%, with operating and profit margins of 13.59% and 4.71%.

Gross Margin	50.42%
Operating Margin	13.59%
Pretax Margin	5.49%
Profit Margin	4.71%
EBITDA Margin	19.44%
EBIT Margin	13.59%
FCF Margin	-35.98%

Dividends & Yields

This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 1.66%.

Dividend Per Share	2.00
Dividend Yield	1.66%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	77.61%
Buyback Yield	-0.00%
Shareholder Yield	1.66%
Earnings Yield	1.73%
FCF Yield	-13.18%

Dividend Details

Stock Splits

The last stock split was on November 27, 2011. It was a forward split with a ratio of 1.05.

Last Split Date	Nov 27, 2011
Split Type	Forward
Split Ratio	1.05

Scores

Beacon Pharmaceuticals has an Altman Z-Score of 4.16.

Altman Z-Score	4.16
Piotroski F-Score	n/a